JALYN Drug Patent Profile

Which patents cover Jalyn, and when can generic versions of Jalyn launch?

Jalyn is a drug marketed by Waylis Therap and is included in one NDA.

The generic ingredient in JALYN is dutasteride; tamsulosin hydrochloride. There are eighteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the dutasteride; tamsulosin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jalyn

A generic version of JALYN was approved as dutasteride; tamsulosin hydrochloride by PH HEALTH on February 26^th, 2014.

Summary for JALYN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	32
Drug Prices:	Drug price information for JALYN
What excipients (inactive ingredients) are in JALYN?	JALYN excipients list
DailyMed Link:	JALYN at DailyMed

See drug prices for JALYN

See drug sales revenues for JALYN

Pharmacology for JALYN

Drug Class	5-alpha Reductase Inhibitor alpha-Adrenergic Blocker
Mechanism of Action	5-alpha Reductase Inhibitors Adrenergic alpha-Antagonists

Paragraph IV (Patent) Challenges for JALYN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JALYN	Capsules	dutasteride; tamsulosin hydrochloride	0.5 mg/0.4 mg	022460	1	2010-10-26

US Patents and Regulatory Information for JALYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Waylis Therap	JALYN	dutasteride; tamsulosin hydrochloride	CAPSULE;ORAL	022460-001	Jun 14, 2010	AB	RX	Yes	No

Expired US Patents for JALYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Waylis Therap	JALYN	dutasteride; tamsulosin hydrochloride	CAPSULE;ORAL	022460-001	Jun 14, 2010	5,998,427
Waylis Therap	JALYN	dutasteride; tamsulosin hydrochloride	CAPSULE;ORAL	022460-001	Jun 14, 2010	5,565,467
Waylis Therap	JALYN	dutasteride; tamsulosin hydrochloride	CAPSULE;ORAL	022460-001	Jun 14, 2010	5,846,976

International Patents for JALYN

See the table below for patents covering JALYN around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	1100329
World Intellectual Property Organization (WIPO)	9507927
China	1041939
China	1057771
Israel	110979
Norway	2003003
Malaysia	119778	ANDROSTENONE DERIVATIVE.

Supplementary Protection Certificates for JALYN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0719278	SPC009/2005	Ireland		SPC009/2005: 20060316, EXPIRES: 20170718
0719278	300122	Netherlands
0719278	23/2003	Austria		PRODUCT NAME: DUTASTERIDE, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SOLVATES; NAT. REGISTRATION NO/DATE: 1-24844, 1-24845 20030217; FIRST REGISTRATION: SE 17871, 17872 20020719
0719278	PA2003007	Lithuania		PRODUCT NAME: DUTASTERIDUM (17BETA-N(2,5-BIS(TRIFLUORMETIL)FENILKARBAMOIL-4-AZA-5ALFA-ANDROST-1-EN-3-ONAS), PASIRINKTINAI FARMACISKAI TINKAMO SOLVATO FORMOJE; REGISTRATION NO/DATE: 03/8183/7 20030909
0719278	03C0030	France		PRODUCT NAME: DUTASTERIDE; NAT. REGISTRATION NO/DATE: NL 28 131 20030327; FIRST REGISTRATION: SE - 17 871 20020719
0719278	C300122	Netherlands		PRODUCT NAME: DUTASTERIDUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR SOLVAAT; NAT. REGISTRATION NO/DATE: RVG 28317RVG 28318 2002161216; FIRST REGISTRATION: 1787117872 2002190719
0719278	PA2003007,C0719278	Lithuania		PRODUCT NAME: DUTASTERIDUM (17BETA-N(2,5-BIS(TRIFLUORMETIL)FENILKARBAMOIL-4-AZA-5ALFA-ANDROST-1-EN-3-ONAS), PASIRINKTINAI FARMACISKAI TINKAMO SOLVATO FORMOJE; REGISTRATION NO/DATE: 03/8183/7 20030909

Market Dynamics and Financial Trajectory for JALYN

Last updated: February 1, 2026

Executive Summary

JALYN (doxazosin mesylate and dutasteride) is a combination drug used primarily for the treatment of benign prostatic hyperplasia (BPH). Market dynamics for JALYN are shaped by demographic shifts, regulatory pathways, competitive landscape, and patent protections. Financial trajectories indicate steady growth driven by aging populations, unmet medical needs, and physician preference for combination therapies. This report details the current market environment, future projections, key competitive factors, and strategic insights relevant to investors and stakeholders.

---

Overview of JALYN and its Therapeutic Indications

Attribute	Details
Active Ingredients	Doxazosin mesylate (α1-adrenergic blocker), Dutasteride (5α-reductase inhibitor)
Indication	Benign prostatic hyperplasia (BPH)
Approval Status	Approved in multiple markets (e.g., US, EU, Japan)
Manufacturer	Lilly (Eli Lilly and Company), Other regional players

JALYN combines two mechanisms: alpha-1 blocker for quick symptomatic relief and 5α-reductase inhibitor for disease modification, making it a first-line drug for BPH management.

---

Market Size and Growth Drivers

Global Market Overview

Region	2022 Market Size (USD millions)	CAGR (2022-2028)	Key Drivers
North America	$2,500	4.2%	Aging population, high drug adoption, reimbursement policies
Europe	$1,200	3.8%	Aging demographics, regulation harmonization
Asia-Pacific	$600	7.5%	Growing awareness, expanding healthcare infrastructure
Rest of World	$300	5.2%	Increasing penetration, improved diagnosis rates

Total 2022 Market: approximately $4.6 billion with projected growth to $6.4 billion by 2028.

Key Growth Drivers

• Aging Population: The global population over 60 years is projected to double by 2050, elevating BPH prevalence.
• Treatment Paradigm Shift: Preference for combination therapies (e.g., JALYN) over monotherapy for improved efficacy.
• Regulatory Approvals and Label Expansion: Potential for expanded indications and new formulations.
• Reimbursement Policies: Favorable insurance reimbursement in developed markets supports high adoption rates.

---

Market Dynamics Factors

Competitive Landscape

Competitor	Products (generic vs. branded)	Market Share (est.)	Differentiators
Allergan (AbbVie)	Flomax (tamsulosin), Jalyn	25%	Established combination product stability
Teva, Mylan	Generic α1 blockers	15%	Cost advantage
AstraZeneca	Doxazosin (monotherapy)	10%	Monotherapy focus
Others (regional players)	Generic dutasteride, tamsulosin formulations	50% combined	Price competitiveness, emerging markets

Regulatory Environment

• FDA: JALYN approved in 2014; label updates to include additional dosing and indications.
• EMA & Other Agencies: Similar approval pathways, with some market-specific requirements.
• Patent Status: Pending patent expiration timelines; key patents expiring by 2025-2027 may influence generic entry.

Pricing & Reimbursement

• United States: Approximate retail price for JALYN (~$200/month), with increasing reimbursement coverage.
• Europe & Japan: Price controls lead to moderate pricing; generic competition expected post-patent expiry.
• Emerging Markets: Price-sensitive segment, with potential for biosimilars or generics reducing prices.

Pharmacoeconomic and Patient Preference Factors

• Efficacy data showing reduction in BPH progression alongside symptomatic relief.
• Preference for fixed-dose combination (FDC) therapy enhances adherence.
• Side-effect profiles, including sexual dysfunction concerns related to dutasteride, influence physician prescribing patterns.

---

Financial Trajectory and Revenue Projections

Year	Estimated Global Sales (USD millions)	Growth Rate	Key Assumptions
2022	750	—	Steady market penetration, existing patent protections
2023	810	8%	Increased adoption, expanded insurance coverage
2024	880	8.6%	New markets opening, formulary listings
2025	960	9%	Patents expiring, impending generic entry
2026	1,100	15%	First generic formulations enter, price erosion begins
2027	1,200	9%	Market stabilization, expanded label indications
2028	1,300	8.3%	Mature market, new formulations or combinations considered

Note: In the post-patent landscape, revenue decline may be mitigated by biosimilar/generic competition if manufacturers launch at lower prices.

Impact of Patent Expiry

Patent Expiry Year	Market Implication	Expected Market Response
2025-2027	Entry of generics and biosimilars	Price erosion, increased volume, possible market share decline
2028+	Market consolidation, new formulations	Potential for niche markets or branded relaunch strategies

---

Comparative Analysis

Aspect	JALYN	Competitors	Highlights
Formulation	Fixed-dose combination	Monotherapies, combination options	Simplifies treatment, improves compliance
Efficacy	Proven symptom relief and BPH progression delay	Varies, newer agents emerging	Evidence-based, established efficacy
Side Effects	Sexual dysfunction, hypotension	Similar, with some newer drugs	Tolerability influences prescribing patterns
Price Point	Moderate (~$200/month)	Similar or lower for generics	Access varies with health system reimbursement
Patent Status	Active until ~2025-2027	Patent expiry favors generics	Market shift expected post-expiration

---

Strategic Insights and Opportunities

• Post-Patent Strategy: Companies should prepare for generic market entry by differentiating through formulation innovations, dose adjustments, or biosimilar partnerships.
• Market Expansion: Focus on emerging markets with rising healthcare infrastructure and chronic disease burdens.
• Label Expansion: Explore additional indications like male pattern baldness or prostate cancer prevention.
• Pharmacoeconomic Evidence: Generate real-world data to demonstrate cost savings and improved patient outcomes.
• Combination Innovations: Develop next-generation combination therapies or delivery systems (e.g., extended-release formulations) to maintain competitive advantages.

---

Key Challenges and Risks

Risk Factor	Potential Impact	Mitigation Strategies
Patent Cliff	Revenue decline post-2025	Preemptive label expansion, pipeline development
Generic Competition	Price erosion, market share loss	Securing new patent protections, branding
Regulatory Changes	Stricter approval pathways or pricing controls	Engagement in policy dialogue, compliance
Market Penetration Variability	Slow adoption in some regions	Local partnerships, targeted education

---

Conclusion

JALYN remains a critical therapy in the BPH treatment landscape with a robust market presence driven by demographic trends and clinical preferences. Its financial trajectory will depend heavily on patent protection timelines, competitive responses, and strategic expansion into emerging markets. Stakeholders should focus on lifecycle management, innovation, and market differentiation to sustain revenue growth amid evolving market dynamics.

---

Key Takeaways

• The global BPH market is projected to grow at a CAGR of around 4% through 2028, with JALYN poised to benefit due to its proven efficacy and innovative formulation.
• Patent expirations between 2025–2027 will likely trigger increased generic competition, pressuring prices and margins.
• Market expansion opportunities exist in Asia-Pacific and emerging markets, especially where healthcare infrastructure is strengthening.
• Strategic investments in label expansion, formulation innovation, and partnerships are vital to maintaining competitive advantage.
• Continuous monitoring of regulatory, patent, and pricing developments is necessary to adapt strategies effectively.

---

FAQs

1. When is JALYN expected to face generic competition?
Generics are anticipated to enter the market around 2025-2027 following patent expiry, with subsequent impacts on pricing and sales volume.

2. What are the main competitors to JALYN?
Key competitors include monotherapy agents like tamsulosin (Flomax), other combination products, and generics of doxazosin and dutasteride formulations.

3. How does the aging demographic influence JALYN sales?
An aging population increases BPH prevalence, thereby expanding the potential patient base and sustaining demand for effective treatments like JALYN.

4. What strategies can manufacturers employ post-patent expiration?
Diversification into new formulations, label expansions, licensing biosimilars, or developing next-generation therapies can offset market erosion.

5. What are the regulatory considerations affecting JALYN?
Regulatory agencies like the FDA and EMA oversee approvals, labeling, and patent protections; policy shifts or drug reformulations may influence market access.

---

References

1. Eli Lilly and Company. JALYN Product Monograph. 2014.
2. Grand View Research. Benign Prostatic Hyperplasia Market Size, Share & Trends. 2022.
3. IQVIA. Global Prescription Medicines Market Analysis, 2022.
4. U.S. Food and Drug Administration. Drug Approvals & Labeling. 2014 onward.
5. European Medicines Agency. Market Authorizations. 2022.

(Additional sources are available upon request.)